Related Experiment Videos
[Effect of platelet activating factor on TxA2, PGI2 and Ca(2+)-ATPase activity in the intra-pulmonary artery smooth
Abstract:
The effects of exogenous platelet activating factor (PAF), BN52021 (an antagonist of PAF receptor), indomethacin and verapamil on the production of TxA2, PGI2 and activity of Ca(2+)-ATPase were investigated in rabbit intra-pulmonary smooth muscle cells (PASMCs). The results were as follows: (1) Under basic condition, active AA metablism was present in PASMCs. (2) Significant increase of TxA2 and PGI2 but not their ratio may result from binding of PAF receptor and activation of cyclooxgenase. (3) Activity of Ca(2+)-ATPase could be inhibited by exogenous PAF. (4) The inhibitory effect of PAF on PASMCs Ca(2+)-ATPase could be reversed by verapamil.
Insights
Platelet activating factor (PAF) affects calcium levels in pulmonary smooth muscle cells by influencing thromboxane A2 (TxA2) and prostacyclin (PGI2) production. Verapamil can reverse PAF
Area of Science:
- Pharmacology
- Cell Physiology
- Biochemistry
Background:
- Platelet-activating factor (PAF) is a lipid mediator involved in various physiological and pathological processes.
- Pulmonary artery smooth muscle cells (PASMCs) play a crucial role in regulating vascular tone.
- Understanding the molecular mechanisms underlying PASMC function is essential for treating respiratory diseases.
Purpose of the Study:
- To investigate the effects of exogenous platelet activating factor (PAF) on thromboxane A2 (TxA2), prostacyclin (PGI2) production, and Ca(2+)-ATPase activity in rabbit PASMCs.
- To determine the role of PAF receptors, cyclooxygenase, and calcium channels in these cellular responses.
Main Methods:
- Rabbit PASMCs were treated with PAF, a PAF receptor antagonist (BN52021), indomethacin, and verapamil.
- Measurements included TxA2 and PGI2 production and Ca(2+)-ATPase activity.
- Arachidonic acid (AA) metabolism was assessed under basal and stimulated conditions.
Main Results:
- PASMCs exhibited active arachidonic acid metabolism under basal conditions.
- PAF stimulation led to a significant increase in TxA2 and PGI2 production, suggesting cyclooxygenase activation.
- Exogenous PAF inhibited Ca(2+)-ATPase activity, indicating a role for calcium signaling in PAF's effects.
- Verapamil, a calcium channel blocker, reversed the inhibitory effect of PAF on Ca(2+)-ATPase.
Conclusions:
- PAF modulates TxA2 and PGI2 production in PASMCs, likely via receptor binding and cyclooxygenase activation.
- PAF exerts an inhibitory effect on Ca(2+)-ATPase activity in PASMCs.
- Verapamil can counteract the inhibitory effects of PAF on Ca(2+)-ATPase, highlighting the involvement of calcium influx.